Astrin Biosciences

About Astrin Biosciences

Headquartered in Saint Paul, Minnesota, Astrin Biosciences is a cancer intelligence company founded in 2020 by Jayant Parthasarathy. The inspiration to establish the firm came after Parthasarathy's father was diagnosed with cancer, a personal experience that drove him to assemble a multidisciplinary team of researchers, engineers, and clinicians. The company operates at the intersection of deep proteomics, artificial intelligence, and cancer biology, aiming to shift the paradigm of cancer detection and treatment.

Astrin Biosciences is developing a platform focused on early cancer detection through non-invasive tests. Its core technology analyzes over 7,000 proteins from less than a milliliter of blood plasma to identify the earliest molecular signals of cancer, which are often missed by traditional imaging and genetic tests. The company employs a proprietary method that combines AI-powered 3D holographic imaging with deep learning to decode faint protein signals, creating a comprehensive molecular fingerprint that can distinguish between healthy individuals and those with early-stage cancer. This approach is designed to guide patients toward personalized care that fits their specific biology.

The company's business model is centered on the development and commercialization of these diagnostic tools. A significant milestone includes a research collaboration with Memorial Sloan Kettering Cancer Center to advance biomarker development for cancer treatment. In June 2024, the company secured $22.9 million in a Series A funding round, bringing its total raised capital to a similar figure across two rounds. This funding supports the pre-commercial development of its first product, Certitude, an early detection test for women with dense breasts. Astrin's clients are expected to include healthcare providers and institutions focused on oncology and precision medicine.